Conflict of interest
Hutchinson Medipharma LTD, MPM, P.
ONCOLOGY
R. Kim reports honoraria fees from Pfizer and QED; and consulting fees from Incyte, Bayer, and Taiho. A. D. Leal reports employment with ClinicalPath Oncology, as a Pancreatic/Neuroendocrine Committee Chair; and research funds from Bristol Myers Squibb (Institution, Exelixis (Institution), Arrys Therapeutics, Inc. (Institution), Hutchinson Medipharma LTD (Institution), Corcept Therapeutics (Institution), AbbVie (Institution), and Conjupro Biotherapeutics, Inc (Institution). A. Parikh reports ownership of stock/shares from Equity for C2i genomics for SAB; consulting fees from Pfizer, Eli Lilly, Roche, and Inivita and other potential financial relationships with research to the institution Puretech in the last 12 months, PMV Pharma, Plexxicon, Takeda, Bristol Myers Squibb, Novartis, Mirati, Genentech, and Daiichi Sankyo. D. P. Ryan reports ownership of stock/shares from MPM Capital and Exact Sciences, honoraria fees from MPM Capital, consulting fees from Boehringer Ingelheim, grants or funds from SU2C, and other potential financial relationships with UpToDate and McGraw Hill. S. Wang reports potential employment conflict and ownership of stock/shares with Takeda Inc. B. Bahamon reports potential employment conflict with Takeda Development Center Americas, Inc. N. Gupta and H. Miao report potential employment conflict and ownership of stock/shares with Takeda. A. Moss reports consulting fees with Takeda. J. Pye reports potential employment conflict with Takeda. H. Inguilizian reports potential employment conflict with Takeda Pharmaceutical. J. M. Cleary reports honoraria fees from Syros Pharmaceuticals and Blueprint Medicines; grants/funds from AbbVie (Institution), Merus (Institution), Roche (Institution), Bristol Myers Squibb (Institution), Merck, AstraZeneca, Esperas Pharma, Bayer, and Tesaro.